• Topics

  • Formats

Real-world evidence (RWE) plays an increasingly important role - as a complement to traditional clinical trial data - in informing the safety, effectiveness and value of healthcare interventions. Considerations as to when and where to pull in digital health device data as a source of RWE will form the cornerstone of future data strategies spearheaded by the medical affairs function in biopharma.

Are you a medical affairs executive keen to upskill in digital health? In this masterclass, you will learn how to design your evidence strategy leveraging digital health solution data. We will cover:

  • Patient oriented real world evidence generation planning with digital health solutions – ensuring data generated optimises patient experiences
  • Considerations for how to optimise your RWE data strategy to fill existing knowledge gaps
  • How to build a resilient data framework that enables identification of optimal data sources and robust derivation of meaningful outcomes from digital health solutions.

We would like to remind you that our meetings are small and intimate sessions with a limited number of seats available, therefore we rely on your attendance and participation to ensure a high quality and valuable meeting for all. If you are confirmed for this meeting we ask if you can please ensure your attendance on the day.

Kelly Brassil, Director Research and Real World Evidence, Pack Health

Alette Brinth, Digital Innovation Associate Director, Novartis

Rick Bartels, Managing Partner , DTxCC

Christina Kotsi, Digital Lead, Global Medical Affairs, Bayer

Janet Munro, Digital Program Head, Novartis US

Valéry Risson, WorldWide HEOR Director Neuroscience at Novartis

Kevin Darcy, Director, Link Strategy at Veeva Systems

Available Dates

You are attempting to log out of MyMA

Do you really want to log out?